InvestSMART

Austco Healthcare Limited (ASX:AHC)

ALERT: Price-sensitive ASX Announcement for AHC
Current share price for AHC : $0.240 -0.135 (-36%)+
Announcement
Release
26 Aug 2025 8:55AM
Price at Release
$0.375
Full Release
download
Summary
Austco Healthcare Limited (AHC) achieved strong financial results for the year ended 30 June 2023, highlighted by a turnaround to a net profit after tax of $3.2 million and a 30.5% increase in revenue to $40.9 million. The company experienced growth across all markets, driven by robust demand in the healthcare sector and the successful rollout of its software and SaaS offerings, leading to improved gross margins and a record order book. Operational enhancements resulted in a 120% rise in underlying EBITDA to $5.4 million. With a healthy cash position and no debt, Austco continues to invest in product and market expansion, while acknowledging ongoing risks related to supply chain issues and inflation. The directors are optimistic about future growth opportunities, as detailed in the Appendix 4E and financial statements.
Key Points
  • Austco Healthcare Limited (AHC) reported a statutory net profit after tax of $3.2 million for the year ended 30 June 2023, a significant turnaround from the previous year’s loss.
  • Revenue increased by 30.5% to $40.9 million, driven by growth across all markets and a record order book.
  • Underlying EBITDA for the year was $5.4 million, up by 120% compared to the prior year, reflecting operational improvements and growth in higher-margin software sales.
  • The company benefited from a robust healthcare sector demand and successful implementation of its SaaS strategy.
  • Gross margins improved due to a higher proportion of software and SaaS revenue versus hardware sales.
  • Strong cash flow was reported, ending with a cash balance of $10.7 million, with no debt.
  • Austco is investing in product development, particularly with the continuing rollout of its Tacera and SaaS platforms.
  • The company did not declare a final dividend for FY23.
  • Directors are optimistic about FY24, highlighting the growing sales pipeline, new orders, and expansion into new geographical markets.
  • Risks remain related to supply chain disruptions, inflationary pressures, and labor shortages, but mitigation strategies are in place.
  • The Appendix 4E and financial statements confirm compliance with reporting standards and provide a comprehensive overview of the company’s financial position and performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.